NO20015909L - Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2 diabetes, hyperlipidemi og hyperurisemi - Google Patents

Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2 diabetes, hyperlipidemi og hyperurisemi

Info

Publication number
NO20015909L
NO20015909L NO20015909A NO20015909A NO20015909L NO 20015909 L NO20015909 L NO 20015909L NO 20015909 A NO20015909 A NO 20015909A NO 20015909 A NO20015909 A NO 20015909A NO 20015909 L NO20015909 L NO 20015909L
Authority
NO
Norway
Prior art keywords
trihalomethylphenoxy
hyperuricemia
halophenyl
hyperlipidemia
diabetes
Prior art date
Application number
NO20015909A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015909D0 (no
Inventor
Kenneth L Luskey
Original Assignee
Diatex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23270381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20015909(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Diatex Inc filed Critical Diatex Inc
Publication of NO20015909D0 publication Critical patent/NO20015909D0/no
Publication of NO20015909L publication Critical patent/NO20015909L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20015909A 1999-06-04 2001-12-03 Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2 diabetes, hyperlipidemi og hyperurisemi NO20015909L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/325,997 US6262118B1 (en) 1999-06-04 1999-06-04 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
PCT/US2000/015235 WO2000074666A2 (en) 1999-06-04 2000-06-02 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia

Publications (2)

Publication Number Publication Date
NO20015909D0 NO20015909D0 (no) 2001-12-03
NO20015909L true NO20015909L (no) 2002-01-15

Family

ID=23270381

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015909A NO20015909L (no) 1999-06-04 2001-12-03 Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2 diabetes, hyperlipidemi og hyperurisemi

Country Status (32)

Country Link
US (6) US6262118B1 (zh)
EP (2) EP1614418B1 (zh)
JP (2) JP4685300B2 (zh)
KR (2) KR100779787B1 (zh)
CN (2) CN100379412C (zh)
AR (1) AR042574A1 (zh)
AT (2) ATE336235T1 (zh)
AU (1) AU775909C (zh)
BR (1) BR0011342A (zh)
CA (2) CA2371723C (zh)
CL (1) CL2011001971A1 (zh)
CO (1) CO5170453A1 (zh)
CY (1) CY1112861T1 (zh)
CZ (1) CZ20014341A3 (zh)
DE (1) DE60030109T2 (zh)
DK (2) DK1614418T3 (zh)
ES (2) ES2269151T3 (zh)
HK (2) HK1045111B (zh)
HU (1) HUP0201611A3 (zh)
IL (3) IL146914A0 (zh)
MX (1) MXPA01012435A (zh)
NO (1) NO20015909L (zh)
NZ (2) NZ515902A (zh)
PE (1) PE20010220A1 (zh)
PT (2) PT1614418E (zh)
RU (2) RU2281762C2 (zh)
SA (1) SA00210535B1 (zh)
SK (1) SK17562001A3 (zh)
TW (1) TWI264303B (zh)
UA (1) UA74147C2 (zh)
WO (1) WO2000074666A2 (zh)
ZA (3) ZA200300888B (zh)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
CA2405440A1 (en) * 2000-04-12 2001-10-25 Puracyp Compositions and methods for induction of proteins involved in xenobiotic metabolism
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
WO2002064094A2 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE60326232D1 (de) * 2002-06-03 2009-04-02 Novartis Ag Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
CA2488617A1 (en) * 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
CA2529774C (en) 2003-06-20 2014-05-27 Metabolex, Inc. Resolution of .alpha.-(phenoxy)phenylacetic acid derivatives
US7199259B2 (en) * 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
CN100525757C (zh) * 2003-06-20 2009-08-12 麦它波莱克斯股份有限公司 α-(苯氧基)苯乙酸衍生物的拆分
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
RU2006133284A (ru) * 2004-02-18 2008-03-27 Метаболекс Альфа-(трифторметилзамещенные арилокси, ариламино, арилтио или арилметил)трифторметилзамещенные фенилуксусные кислоты и производные как противодиабетические средства
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
EP1865954A4 (en) * 2005-03-21 2010-12-15 Metabolex Inc METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER
CA2606279C (en) * 2005-04-20 2015-01-06 Metabolex, Inc. Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto
CA2615118A1 (en) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar.gamma. agonist
EP1906934A4 (en) * 2005-07-14 2012-03-07 Franco Folli DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
US7432394B2 (en) * 2005-09-23 2008-10-07 Metabolex, Inc. Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines
US7714131B2 (en) * 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
WO2007114315A1 (ja) * 2006-03-30 2007-10-11 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
EP2010475A2 (en) * 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
KR100788454B1 (ko) * 2006-06-15 2007-12-24 대원제약주식회사 속효성이 증진된 나테글리니드를 유효성분으로 함유하는약제학적 조성물
KR20090047546A (ko) 2006-09-07 2009-05-12 니코메드 게엠베하 당뇨병을 위한 조합 치료
US8604245B2 (en) 2007-06-04 2013-12-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US20110021468A1 (en) * 2007-07-03 2011-01-27 Joslin Diabetes Center, Inc. Treatment of cardiovascular disease with salicylates
WO2009046371A1 (en) * 2007-10-05 2009-04-09 Metabolex, Inc. Methods of treating metabolic diseases
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
WO2009121940A1 (en) * 2008-04-03 2009-10-08 Janssen Pharmaceutica Nv Process for the preparation of (-)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
JP6047172B2 (ja) * 2011-11-04 2016-12-21 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 患者部分集団における痛風の治療方法
MX357510B (es) * 2011-11-04 2018-07-12 Cymabay Therapeutics Inc Metodos para tratar ataques de gota.
CA2859686C (en) * 2011-11-04 2018-09-11 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
AU2013245675B2 (en) * 2012-04-13 2017-02-09 Cymabay Therapeutics, Inc. Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
EP2847152A4 (en) * 2012-05-10 2016-03-23 Cellix Bio Private Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
CA2928725A1 (en) 2013-11-05 2015-05-14 Esther Priel Compounds for the treatment of diabetes and disease complications arising from same
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
JP6192142B2 (ja) * 2016-09-13 2017-09-06 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 痛風発赤の治療方法
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN109369471A (zh) * 2018-12-10 2019-02-22 石家庄度恩医药科技有限公司 一种光学活性R-4-氯-α-(3-三氟甲基苯氧基)苯乙酸的制备方法
WO2021236395A1 (en) 2020-05-18 2021-11-25 Cymabay Therapeutics, Inc. Cb-0406 choline salt
US20210355065A1 (en) 2020-05-18 2021-11-18 Cymabay Therapeutics, Inc. CB-0406 tromethamine salt

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378582A (en) * 1964-03-20 1968-04-16 Merck & Co Inc (alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids
US3517051A (en) * 1964-03-20 1970-06-23 Merck & Co Inc Phenoxy substituted phenylacetic acids
NL6712585A (zh) 1966-10-03 1968-04-04
US3517050A (en) 1966-10-03 1970-06-23 Merck & Co Inc Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid
DK133742B (da) 1970-10-30 1976-07-12 Merck & Co Inc Fremgangsmåde til fremstilling af 2-acetamidoethyl-(3-trifluormethylphenoxy)-(4-chlorphenyl)-acetat.
NL7309039A (zh) * 1972-07-13 1974-01-15
US3860628A (en) * 1972-07-13 1975-01-14 Merck & Co Inc Cyanomethyl(3-trifluoromethylphenoxy)(4-chlorophenyl)acetate
US3923855A (en) 1972-07-13 1975-12-02 Merck & Co Inc 2-sulfonyloxyethyl 3-trifluoromethylphenoxy-4{40 -chlorophenyl acetate
US3953490A (en) 1972-07-13 1976-04-27 Merck & Co., Inc. Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile
NL7309571A (zh) 1972-07-28 1974-01-30
US4110351A (en) 1973-04-02 1978-08-29 Richardson-Merrell Inc. Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
IL48707A0 (en) 1974-12-30 1976-02-29 Synthelabo Novel phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4532135A (en) * 1981-02-09 1985-07-30 Edwards K David G Renoprotective treatments employing vasodilator compounds
DE3525284A1 (de) * 1985-07-16 1987-01-29 Boehringer Mannheim Gmbh Neue carbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie arzneimittel, die diese verbindungen enthalten
US5028052A (en) * 1990-05-11 1991-07-02 Miller Omer E Golf mat
DE4111026A1 (de) * 1991-04-05 1992-10-08 Boehringer Mannheim Gmbh Optisch aktive carbonsaeuren sowie diese enthaltende arzneimittel
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
JPH0927811A (ja) * 1995-07-13 1997-01-28 Fujitsu Ltd 輻輳監視制御装置
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5716987A (en) * 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation
US6624194B1 (en) 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6555577B1 (en) * 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6576662B2 (en) * 2000-05-05 2003-06-10 Dr. Reddy's Laboratories Limited Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
DK1517883T3 (da) * 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US7199259B2 (en) * 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
CA2529774C (en) 2003-06-20 2014-05-27 Metabolex, Inc. Resolution of .alpha.-(phenoxy)phenylacetic acid derivatives
ATE500752T1 (de) * 2004-03-16 2011-03-15 Tno Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation

Also Published As

Publication number Publication date
MXPA01012435A (es) 2003-09-10
HUP0201611A2 (en) 2002-10-28
KR100779787B1 (ko) 2007-11-28
CN100379412C (zh) 2008-04-09
CN1189168C (zh) 2005-02-16
IL187605A0 (en) 2008-03-20
RU2005132222A (ru) 2007-04-27
EP1183020B1 (en) 2006-08-16
KR100721219B1 (ko) 2007-05-22
AR042574A1 (es) 2005-06-29
US20100093853A1 (en) 2010-04-15
EP1614418A1 (en) 2006-01-11
IL187605A (en) 2012-07-31
JP2007099784A (ja) 2007-04-19
CA2751187A1 (en) 2000-12-14
BR0011342A (pt) 2002-03-05
DE60030109T2 (de) 2007-02-15
US6646004B1 (en) 2003-11-11
JP4685808B2 (ja) 2011-05-18
NZ528266A (en) 2005-07-29
PE20010220A1 (es) 2001-02-23
CO5170453A1 (es) 2002-06-27
NZ515902A (en) 2004-02-27
CA2751187C (en) 2014-04-22
CA2371723C (en) 2012-08-21
EP1183020A2 (en) 2002-03-06
JP2003501383A (ja) 2003-01-14
EP1614418B1 (en) 2011-09-14
CZ20014341A3 (cs) 2002-11-13
KR20020025063A (ko) 2002-04-03
TWI264303B (en) 2006-10-21
AU5316200A (en) 2000-12-28
WO2000074666A2 (en) 2000-12-14
CY1112861T1 (el) 2016-04-13
IL146914A0 (en) 2002-08-14
SA00210535B1 (ar) 2006-10-11
JP4685300B2 (ja) 2011-05-18
HUP0201611A3 (en) 2003-03-28
CA2371723A1 (en) 2000-12-14
ATE336235T1 (de) 2006-09-15
ATE524173T1 (de) 2011-09-15
DK1183020T3 (da) 2006-11-27
CN1660060A (zh) 2005-08-31
HK1087616A1 (en) 2006-10-20
UA74147C2 (uk) 2005-11-15
US6613802B1 (en) 2003-09-02
DK1614418T3 (da) 2011-10-17
PT1614418E (pt) 2011-11-21
ES2269151T3 (es) 2007-04-01
HK1045111A1 (en) 2002-11-15
ZA200109973B (en) 2003-02-04
CL2011001971A1 (es) 2012-03-30
PT1183020E (pt) 2006-11-30
US8354448B2 (en) 2013-01-15
HK1045111B (zh) 2006-11-17
US20070270490A1 (en) 2007-11-22
ZA200300889B (en) 2004-08-25
AU775909B2 (en) 2004-08-19
AU775909C (en) 2005-06-30
ZA200300888B (en) 2004-06-30
DE60030109D1 (de) 2006-09-28
US20050075396A1 (en) 2005-04-07
WO2000074666A3 (en) 2001-11-08
US6262118B1 (en) 2001-07-17
SK17562001A3 (sk) 2002-10-08
KR20060122983A (ko) 2006-11-30
IL146914A (en) 2008-07-08
ES2371476T3 (es) 2012-01-03
CN1368879A (zh) 2002-09-11
NO20015909D0 (no) 2001-12-03
RU2281762C2 (ru) 2006-08-20

Similar Documents

Publication Publication Date Title
NO20015909L (no) Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2 diabetes, hyperlipidemi og hyperurisemi
NO20020764L (no) Benzosyrederivater for behandling av diabetes mellitus
EP1343493A4 (en) USE OF (-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
HK1046240B (zh) 治療胰島素抵抗的藥物組合物
NO20022087L (no) Fremgangsmåte for behandling av diabetes
ATE297384T1 (de) Thiazol- und oxazol-derivate und ihre pharmazeutische verwendung
HUP0204574A3 (en) Propionic acid derivatives and their use in the treatment of diabetes and obesity, pharmaceutical compositions containing them and their preparation
NO20020374D0 (no) Karboksylsyreamider, medikamenter inneholdende disse forbindelser, deres anvendelse og fremstilling
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
NO20013958L (no) Legemiddel for behandling av höyt blodtrykk
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
PL378130A1 (pl) Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
NO20043483L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
EP1517883B8 (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
DE69924527D1 (de) Arylalkanoylderivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zubereitungen
AU5847400A (en) Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy
NO20021135L (no) Monomere analoger av human insulin
PT1517679E (pt) Derivados do ácido benzóico substituído na posição orto para o tratamento de resistência à insulina
NO20025883D0 (no) Tiazolidinonsalt for behandling av diabetes mellitus
UA34041A (uk) Спосіб лікування цукрового діабету
AU2001295752A1 (en) Test for the diagnosis of diabetes and compounds for the treatment thereof
ZA200204800B (en) Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity.
ZA200204799B (en) Propionic acid derivatives and their use in the treatment of diabetes and obesity.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application